Bristol-Myers Squibb, Meso Scale Discovery collaborate to progress AD research Bristol-Myers Squibb Firm and Meso Level Discovery today announced they have got entered an agreement to build up diagnostic assays that will measure cerebrospinal liquid biomarkers for make use of in Alzheimer’s disease study. Meso Level Discovery will commercialize the assays for Alzheimer’s disease research and drug advancement, and plans to release the assays in the second quarter of 2012. Terms of the agreement weren’t disclosed prescription medication .